Investor Presentaiton

Investor Presentation First six months of 2018. The GLP-1 segment accounts for 15% of total diabetes care market value in North America Slide 68 North America GLP-1 market GLP-1 value in DKK billion VictozaⓇ dulaglutide OzempicⓇ other exenatide Share of total diabetes care . 60 market 14% Key observations for Victoza® in the US market VictozaⓇ value market share within the GLP-1 segment is 54%¹ 50 12% CAGR value¹: 37.6% Around 80% of Commercial and around 90% of Medicare Part D GLP-1 market volume is covered without restrictions² 10% 40 8% 30 . Around 90% of new patients who start on VictozaⓇ transition from outside of GLP-1 segment³ 6% 20 4% • 10 2% Around 70% of prescriptions are for the higher dose 1.8 mg4 0 0% May 2013 May 2018 1 CAGR for 5-year period Source: IQVIA monthly MAT May, 2018 value figures (DKK) changing diabetes® 1. Source: IQVIA NSP monthly, MAT May 2018 2. FingerTip Formulary bridge/ May 2018 Nomenclature and Xponent PlanTrak only considers bridged volume; excludes cash and mail order data; 3. IQVIA SOB, June 2018 + 4. IQVIA, NPA, June 2018. novo nordisk

View entire presentation